SUBRAMANYAM, Chakrapani,GREEN, Michael Eric,GRAY, David Lawrence Firman,ZHANG, Lei,BRODNEY, Michael Aaron
申请号：
PE0021262016
公开号：
PE00092017A1
申请日:
2015.04.09
申请国别(地区):
PE
年份:
2017
代理人:
摘要：
Relates to compounds of formula (i) wherein R1 and R2 are each h, halogen, alkyl (C1 - C6, among others R3 and R4 are each h, Oh, halogen, NO2, among others Q1 is a heteroaryl 5 to 10 members, heterocicloalquilo 4 to 12 members or phenyl L1 is o, S, C (= o) CH (OH), among others T6 Is H, halogen, Oh,CN or c1-c2 is n or C - X1 x2 is n or C T1 T2 X3 is n or C T3 T4 is n or C - X4, X5 is n or C - T5, where T1, T2, T3, T4 and T5 are each h, Oh, c1-c4 alkyl, among others. Preferred compounds are: 1.5 - dimethyl - 6 - [4 - (2 - methyl - 2 - 8 - naftiridin iloxi) phenyl] pyrimidine 2,4 (1H, 3H) - dione 4.6 - dimethyl - 5 - [2 - (2 - methyl - 4 - 8 - naftiridin iloxi) phenyl] piridazin - 3 (2H) - One among others.It also relates to a Pharmaceutical composition. These compounds are ligands of dopamine D1 being useful in the treatment of schizophrenia, anxiety, depressionSE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, CN, ALQUILO C1-C6, ENTRE OTROS R3 Y R4 SON CADA UNO H, OH, HALOGENO, NO2, ENTRE OTROS Q1 ES UN HETEROARILO DE 5 A 10 MIEMBROS, HETEROCICLOALQUILO DE 4 A 12 MIEMBROS O FENILO L1 ES O, S, C(=O), CH(OH), ENTRE OTROS T6 ES H, OH, HALOGENO, CN O ALQUILO C1-C2 X1 ES N O C-T1 X2 ES N O C-T2 X3 ES N O C-T3 X4 ES N O C-T4 X5 ES N O C-T5, DONDE T1, T2, T3, T4 Y T5 SON CADA UNO H, OH, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1,5-DIMETIL-6-[2-METIL-4-(1,7-NAFTIRIDIN-8-ILOXI)FENIL]PIRIMIDIN-2,4(1H,3H)-DIONA 4,6-DIMETIL-5-[2-METIL-4-(1,7-NAFTIRIDIN-8-ILOXI)FENIL]PIRIDAZIN-3(2H)-ONA ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE DOPAMINA D1 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, ANSIEDAD, DEPRESION
